Celgene Stock

CELG

Delayed Nasdaq 04:00:00 2019-11-20 pm EST			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

21-04-07	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
21-03-25	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
21-02-02	BX Swiss AG startet Handel in neuem Bondsegment
20-07-07	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
20-07-03	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 68.61B 62.92B 57.2B 108B 7,290B 110B 749B 301B 3,853B 289B 283B 12,197B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 81.28B 74.53B 67.76B 128B 8,636B 130B 887B 356B 4,564B 342B 335B 14,448B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
21-06-21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
21-02-22	Celgene Corporation Issues Notice of Redemption of Notes	CI
21-02-04	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
21-01-04	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
20-12-22	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
20-11-05	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
20-09-22	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
20-09-21	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
20-03-25	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
20-03-10	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
20-03-04	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

23-02-28	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
22-08-24	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
22-07-29	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
22-02-24	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
21-08-04	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.58B 10.62B 9.66B 18.17B 1,230B 18.57B 126B 50.73B 650B 48.8B 47.76B 2,059B	15.28B 13.61B 12.48B 11.35B 21.35B 1,446B 21.82B 149B 59.62B 764B 57.35B 56.12B 2,419B
Net income	2.94B 2.62B 2.4B 2.18B 4.11B 278B 4.2B 28.58B 11.47B 147B 11.03B 10.8B 465B	4.05B 3.6B 3.3B 3B 5.65B 383B 5.78B 39.33B 15.79B 202B 15.18B 14.86B 641B
Net Debt	3.79B 3.38B 3.1B 2.82B 5.3B 359B 5.42B 36.88B 14.8B 190B 14.24B 13.93B 601B	14.22B 12.67B 11.61B 10.56B 19.87B 1,346B 20.31B 138B 55.49B 711B 53.37B 52.23B 2,252B

Celgene Stock

Stocks

CELG

Valuation: Celgene

Latest news: Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile